Our people

Dr. Himanshu Gadgil brings with him 24 years of experience in the pharmaceutical industry. He is the Chief Executive Officer at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his leadership, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company.

Previously, as Sr. Vice President at Intas Pharmaceutical Ltd., he revitalized the commercial product pipeline, launching several biosimilar products globally. During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization.

Dr. Gadgil holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.

Dr. Abhishek Mathur is a seasoned healthcare executive with over 17 years of expertise in Biologics R&D, Product Development, and Operations. With a proven track record of interdisciplinary leadership across various functions spanning early research to product commercialization, his extensive experience reinforces our commitment to innovation and patient-centricity. Prior to joining Enzene, he held prominent roles at pioneering biopharmaceutical firms like Amgen and Regeneron in the US, where he successfully guided numerous products from early development to commercialization.

Dr. Mathur holds a Chemical Engineering degree from IIT Bombay, a PhD in Biological Sciences from Northwestern University (USA) and an MBA from Duke University (USA). At Enzene, Abhishek heads Research and Development operations, guiding the team in innovative strategies and ensuring the smooth execution of projects to achieve the company's goals in biotechnology advancements.

Ravishankar Kasturi is the head of manufacturing operations at Enzene Biosciences. His extensive experience includes assignments at Reliance Life Sciences, as head of manufacturing and process development, followed by Dr. Reddy’s Biologics, and Uni-Sankyo ltd.

Ravi is a biochemical engineer by training with a bachelors in pharmacy. He has also completed executive management from the Indian Institute of Management Bangalore (IIMB), India.

Ravi leads all aspects of manufacturing processes of biologics/biosimilars, forming a diversified portfolio of products which include proteins derived from microbial fermentation and mammalian cell culture.

Lourdes Gonzalez-Novo bring over 20 years of overall experience in the pharmaceutical industry. She is a strategic, innovative and critical thinker with the ability to identify and develop profitable business ventures. Her career spans global multinational companies such as Recipharm, Syngene International Limited, IDT Biologika Gmbh, Sandoz pharmaceutical.

In her role at Enzene, Lourdes oversees the commercial aspects of Enzene's two verticals, the biosimilar product pipeline and CDMO services—ensuring optimal market positioning and driving growth across these key business areas.

Viral Shah joined Enzene Biosciences as the Chief Financial Officer in August 2018. He is a Qualified Chartered Accountant from Institute of Chartered Accountants, India and a commerce graduate from Narsee Monjee College of Commerce and Economics.

Prior to Enzene, Viral was a Director in Advisory Practice of Ernst & Young LLP at Mumbai, focusing on Lifesciences sector and he spent 11+ years conducting extensive advisory work in Pharma on matters related to Governance, Risk and Compliance. He led projects in nature of Internal auditing, GST Advisory, designing procedures and authority matrix, Risk Management, SOX, IFC, Compliance & Contract Management framework, Cost reduction.

At Enzene, he plays a pivotal role in Financial Planning, Budgeting & Forecasting including financial evaluation of all strategic decisions, building scenarios and recommending actions. He leads all financial aspects such as Corporate Finance, Financial planning and analysis, Treasury, Taxation, R&D and manufacturing finance, Manufacturing Finance, Financial Reporting and Asset Management. He also plays a significant role in supervising and leading all strategic initiatives in Procurement functions, Secretarial and Legal functions.

Lata plays a critical role in shaping the organization culture, driving employee engagement and building a high performing workforce. Her extensive experience includes assignments at Cipla, Advinus Therapeutics, Allergan India Pvt. Ltd, Fresenius Kabi.

She holds a BSc. in Microbiology from Ramnarian Ruia College. She also holds a MBA in Human resource management from the SIES College of management studies, India.

Lata leads the design, implementation and execution of HR strategy, organizational design, and development for creating a global organization for Enzene. She also leads EHS efforts in fostering a culture of safety, sustainability and compliance. Additionally, in the business operation role she plays a pivotal part in enhancing the effectiveness, efficiency and impact of the CEO office by executing strategic plans, initiatives, and organizational priorities based on key data analytics and work flows.

Dr. Sundar Ramanan brings over 25 years of experience across biopharmaceutical drug development to commercialization lifecycle, with strong emphasis on Quality and Regulatory compliance. His career spans both product development global companies such as Amgen, Baxter and Biocon, and CDMO Just-Evotec biologics. His notable accomplishments include FDA and EMA cGMP approval for manufacturing facilities, advancing regulatory policy with FDA leading to Phase-3 waiver for insulin and thereby enabling the 1st FDA approval for a biosimilar with interchangeability rating without Phase-3 in the US.

Dr. Ramanan is chemical Engineer by training and holds a PhD in Bioengineering from Oregon State University and an MBA from University of Michigan. He is also an accomplished speaker and author. His most recent publication is a book titled “Orphan Drug Development for Rare Disease” RAPS 2021.

As CQO, Sundar will oversee the quality unit in India and lead its expansion into the U.S. market. In India, he will manage the quality operational functions, including QA and QC, while also overseeing the centralized quality system and the quality engineering & validation units.

With over 25 years in the biopharmaceutical industry, his experience includes progressive leadership roles in Manufacturing, Validation, Quality Assurance, and Network Strategy. Norm has extensive clinical manufacturing experience with mAb and AAV processes, along with commercial experience in mAb drug substance production.

He has been part of 4 successful biopharmaceutical manufacturing facility start-ups. Prior to joining us, Norm served as the Site Head & Head of Biologics Manufacturing at PTC Therapeutics. Before that, he served as Director, Clinical Manufacturing & Business Operations at Bristol-Myers Squibb. Earlier in his career, Norm worked in manufacturing and validation roles at Centocor (J&J) and JRH Biosciences. Norm has Bachelor of Science – Biology from State University of New York – New Paltz.